Your browser doesn't support javascript.
loading
Best treatment options for occult breast cancer: A meta-analysis.
Wang, Rong; Yang, Hong-Xin; Chen, Jie; Huang, Jian-Jun; Lv, Qing.
Afiliación
  • Wang R; Department of Breast Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Yang HX; Department of Breast Surgery, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
  • Chen J; Department of General Surgery, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
  • Huang JJ; Department of Breast Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Lv Q; Department of Breast Surgery, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
Front Oncol ; 13: 1051232, 2023.
Article en En | MEDLINE | ID: mdl-37251927
Objectives: Occult breast cancer (OBC) is a rare malignant breast tumor. Because of the rare cases and limited clinical experience, a huge therapeutic difference has existed all over the world and standardized treatments have yet been established. Methods: A meta-analysis was conducted using MEDLINE and Embase databases to identify the choice of OBC surgical procedures in all studies: (1) patients undergoing axillary lymph node dissection (ALND) or sentinel lymph node biopsy (SLNB) only; (2) patients undergoing ALND with radiotherapy (RT); (3) patients undergoing ALND with breast surgery (BS); (4) patients undergoing ALND with RT and BS; and (5) patients undergoing observation or RT only. The primary endpoints were mortality rates, the second endpoints were distant metastasis and locoregional recurrence. Results: Among the 3,476 patients, 493 (14.2%) undergo ALND or SLNB only; 632 (18.2%) undergo ALND with RT; 1483 (42.7%) undergo ALND with BS; 467 (13.4%) undergo ALND RT and BS, and 401 (11.5%) undergo observation or RT only. After comparing the multiple groups, both groups 1 and 3 have higher mortality rates than group 4 (30.7% vs. 18.6%, p < 0.0001; 25.1% vs. 18.6%, p = 0.007), and group 1 has higher mortality rates than groups 2 and 3 (30.7% vs.14.7%, p < 0.00001; 30.7 vs. 19.4%, p < 0.0001). Group (1 + 3) had a prognosis advantage over group 5 (21.4% vs. 31.0%, p < 0.00001). There was no significant difference both in the distant recurrence rates and locoregional rates between group (1 + 3) and group (2 + 4) (21.0% vs. 9.7%, p = 0.06; 12.3% vs. 6.5%, p = 0.26). Conclusion: On the basis of this meta-analysis, our study indicates that BS including modified radical mastectomy (MRM) and breast-conserving surgery (BCS) combined RT may appear as the optimal surgical approach in patients with OBC. RT cannot prolong both the time of distant metastasis and the local recurrences.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Systematic_reviews Idioma: En Revista: Front Oncol Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Systematic_reviews Idioma: En Revista: Front Oncol Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza